Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by B. Blaser
Phase I Dose-Escalation Study of Venetoclax Plus Beam Followed by Autologous Stem Cell Transplant (Asct) for Chemoresistant, Relapsed/Refractory, or High-Risk Non-Hodgkin's Lymphoma (Nhl); Preliminary Results
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Autologous Stem Cell Transplantation (ASCT) Is Effective Therapy for Older Patients With Non-Hodgkin's Lymphoma (NHL)
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Phase Iiib Study of Lenalidomide Plus Rituximab Followed by Maintenance in Relapsed or Refractory Nhl: Analysis of Marginal Zone Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase I Trial of 19-28z Car-T Cells Post-High Dose Therapy and Autologous Transplantation (Hdt-Asct) for Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Brentuximab Vedotin Salvage Followed by Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in High Risk Relapsed Refractory Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
High-Dose Chemotherapy With Carboplatin, Etoposide and Ifosfamide Followed by Autologous Stem Cell Rescue in Patients With Relapsed or Refractory Malignant Lymphomas: A Phase I/Ii Study
Bone Marrow Transplantation
Transplantation
Hematology
